TEVA Should I Buy

Piper Sandler analyst David Amsellem raised the firm's price target on Teva to $41 from $40 and keeps an Overweight rating on the shares after meeting with management. Key discussion topics included a number of bigger picture considerations, including management's approach to innovative R&D and its vision for the R&D organization; how the team is thinking about further build-out of its core neuroscience and immunology verticals; its vision for the biosimilars business; and the approach to capital deployment amid growth in cash generation. With an attractive long-term top-line/EBITDA growth story coming into focus, in the context of continued improvement in the capital structure and an absence of loss of exclusivity exposure, the firm would argue for further multiple expansion from a current EV/2026 EBITDA of 10 times.